Clovis Oncology Inc
Change company Symbol lookup
Select an option...
CLVS Clovis Oncology Inc
ASLN Aslan Pharmaceuticals Ltd
WYND Wyndham Destinations Inc
GRWWF Great Wall Pan Asia Holdings Ltd
BAC Bank of America Corp
FULC Fulcrum Therapeutics Inc
T AT&T Inc
F Ford Motor Co
JNJ Johnson & Johnson
HHER Her Imports

Health Care : Biotechnology | Small Cap Growth
Company profile

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).


Last Trade
0.03 (0.55%)
B/A Size

Market Hours

Closing Price
Day's Change
0.00 (0.00%)
Bid close
Ask close
B/A Size
Day's High
Day's Low

10-day average volume:



6 providers
August 06, 2020
Clovis Oncology Announces Second Quarter 2020 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2020, and provided an update on the Company's clinical development programs and regulatory and commercial outlook for the rest of the year. (BusinessWire)

August 05, 2020
Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today treatment of the first patient in the Phase 2 portion of the LIO-1 trial evaluating the combination of lucitanib, Clovis' investigational angiogenesis inhibitor, including vascular endothelial...(BusinessWire)

July 23, 2020
Clovis Oncology to Announce Second Quarter 2020 Financial Results and Host Webcast Conference Call on August 6

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2020 financial results on Thursday, August 6, 2020, after the close of the U.S. financial markets. Clovis' senior management will host a conference call and live audio webcast at...(BusinessWire)

July 22, 2020
Global PARP Inhibitor Market To Grow At A CAGR Of 27.4% Due To Expanding Role Of PARP Inhibitors In Cancer Treatment

Global PARP Inhibitor Market was valued at USD 924 million in 2018 and predicted to grow at an exponential CAGR of 27.4% during the forecast period. The pharmaceutical industry offers an opportunity to PARP inhibitors market in a promising new area...(Globe Newswire)

July 08, 2020
Why Developments for Targeted Therapies Are Expected to Drive Sales for Brain Tumor Drug Market

The global brain tumor drugs market was valued at about $2.4 billion in 2018 and is expected to grow to $3.41 billion at a CAGR of 9.2% through 2022. The brain tumor drugs market consist of sales of drugs which are used to cure a mass growth of...(PR Newswire)

June 23, 2020
Clinical Trials for new Therapies Providing Hope for Metastatic Breast Cancer Patients

Metastatic breast cancer (also called stage IV) is breast cancer that has spread to another part of the body, most commonly the liver, brain, bones, or lungs. Metastatic disease is NOT hopeless. Many people continue to live long, productive lives...(PR Newswire)

June 22, 2020
New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II

Alkermes plc (Nasdaq: ALKS) and Clovis Oncology, Inc. (Nasdaq: CLVS) today announced positive preclinical data from a study designed to evaluate the combination potential of ALKS 4230, Alkermes' investigational engineered interleukin-2 (IL-2)...(PR Newswire)

June 17, 2020
Clovis Oncology to Highlight Rubraca(R) (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that four abstracts showcasing non-clinical data from rucaparib and lucitanib development programs have been accepted for on-demand viewing and publication at the upcoming American Association for...(BusinessWire)

June 10, 2020
Clovis Oncology Announces Completion of Target Enrollment in the ATHENA Trial, a Phase 3 Maintenance Treatment Study in Front-line, Newly-Diagnosed Advanced Ovarian Cancer

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis' Rubraca(R) (rucaparib), a poly (ADP ribose) polymerase inhibitor...(BusinessWire)

May 28, 2020
Clovis Oncology Announces New Recommendations for Rubraca(R) (rucaparib) Tablets in Updated National Comprehensive Cancer Network (NCCN) Guidelines(R) for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the National Comprehensive Cancer Network(R) (NCCN) updated its Clinical Practice Guidelines in Oncology for Prostate Cancer to include new recommendations for Rubraca(R) (rucaparib)...(BusinessWire)

May 27, 2020
Biotech Brief: Global Glioblastoma Multiforme Drug Market Could Exceed $1.4 Billion by 2025

Multiple industry reports project that the global Glioblastoma multiforme (GBM) drugs market is expected to reach nearly $1.4 billion by 2025, expanding at a CAGR of 12.6% during the forecast period, driven by rising geriatric population, growing...(PR Newswire)

May 21, 2020
Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program

Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that six abstracts featuring data from clinical and real-world evidence studies evaluating Rubraca(R) (rucaparib) in multiple tumor types have been accepted for presentation or publication at the...(BusinessWire)

May 18, 2020
Clovis Oncology Announces Pricing of Public Offering of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of 11,090,000 shares of its common stock in an underwritten public offering at a price to the public of $8.05 per share, before underwriting discounts and commissions. Clovis Oncology...(BusinessWire)

Clovis Oncology Announces Proposed Offering of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of common stock. Clovis Oncology intends to offer, subject to market and other conditions, $85 million of shares of its common stock in an...(BusinessWire)

May 15, 2020
Rubraca(R) (Rucaparib) Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Been Treated with Androgen Receptor-Directed Therapy and a Taxane-Based Chemotherapy

--Accelerated approval based on objective response rate (ORR) and duration of response (DOR) data from the TRITON2 clinical triali --44% ORR (95% CI 31, 57) and median DOR not evaluable (95% CI 6.4, NE, range in months at data cutoff 1.7-24.0+) by...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.